Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 InfectionA Randomized Clinical Trial

Posted on by

JAMA
February 1, 2022, Vol 327, No. 5, Pages 409-497
https://jamanetwork.com/journals/jama/currentissue

 

Original Investigation
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 InfectionA Randomized Clinical Trial
Meagan P. O’Brien, MD; Eduardo Forleo-Neto, MD; Neena Sarkar, PhD; et al.
free access has active quiz
JAMA. 2022;327(5):432-441. doi:10.1001/jama.2021.24939
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living with an infected household contact.